As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term growth. Investors looking to capitalize on this trend might consider adding ...
(Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients ...
Intermountain Medical Center in Murray has made medical history as the first hospital in the United States to perform a new ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb, combines ...
An ultrasound gives providers a better view of internal organs. They’re used to help diagnose conditions and monitor ...
CRAWFORDVILLE, Fla. — Emergency crews rushed Friday to rescue people trapped in flooded homes after Helene roared ashore as a ...
UNICEF has reached an agreement with mpox vaccine manufacturer Bavarian Nordic to supply one million doses of the shot for ...
24m
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved ...
The FDA has cleared the implantable Eversense 365 CGM, which can last up to a year without replacement. The device requires ...
The US FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback